Lundbeck starts new study of tablet version of drug

A new phase I study will investigate how a Lundbeck drug is absorbed by the body when administered in tablet form as opposed to capsule form, which is being trialled within a number of indications.
Photo: Martin Lehmann
Photo: Martin Lehmann
BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY CATHERINE BRETT

Drug candidate LU AG06466 is the focus of yet another clinical trial for which Lundbeck is currently recruiting patients.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading